KEROS THERAPEUTICS INC
NASDAQ: KROS (Keros Therapeutics, Inc.)
Last update: 20 hours ago17.48
-0.02 (-0.11%)
| Previous Close | 17.50 |
| Open | 17.71 |
| Volume | 509,364 |
| Avg. Volume (3M) | 897,600 |
| Market Cap | 532,546,848 |
| Price / Earnings (TTM) | 11.21 |
| Price / Earnings (Forward) | 48.78 |
| Price / Sales | 2.91 |
| Price / Book | 0.760 |
| 52 Weeks Range | |
| Earnings Date | 5 Nov 2025 |
| Profit Margin | 1.96% |
| Operating Margin (TTM) | 71.97% |
| Diluted EPS (TTM) | -0.170 |
| Quarterly Revenue Growth (YOY) | 254,413.31% |
| Total Debt/Equity (MRQ) | 2.53% |
| Current Ratio (MRQ) | 19.29 |
| Operating Cash Flow (TTM) | 44.86 M |
| Levered Free Cash Flow (TTM) | 30.29 M |
| Return on Assets (TTM) | -1.01% |
| Return on Equity (TTM) | 0.71% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Keros Therapeutics, Inc. | Bullish | Bearish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | -1.0 |
| Technical Oscillators | 2.0 |
| Average | 0.13 |
|
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 2.31% |
| % Held by Institutions | 109.35% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Madison Avenue Partners, Lp | 30 Sep 2025 | 2,708,218 |
| Western Standard Llc | 30 Sep 2025 | 2,189,882 |
| Alkeon Capital Management Llc | 30 Sep 2025 | 850,511 |
| Logos Global Management Lp | 30 Sep 2025 | 850,000 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 27.00 (Oppenheimer, 54.46%) | Buy |
| Median | 21.00 (20.14%) | |
| Low | 16.00 (Wedbush, -8.47%) | Hold |
| Average | 21.25 (21.57%) | |
| Total | 2 Buy, 2 Hold | |
| Avg. Price @ Call | 17.01 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| B of A Securities | 28 Nov 2025 | 19.00 (8.70%) | Hold | 17.48 |
| Oppenheimer | 12 Nov 2025 | 27.00 (54.46%) | Buy | 17.47 |
| Wells Fargo | 11 Nov 2025 | 23.00 (31.58%) | Buy | 16.90 |
| Wedbush | 06 Nov 2025 | 16.00 (-8.47%) | Hold | 16.17 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 20 Nov 2025 | Announcement | Keros Therapeutics Announces Final Results of Tender Offer |
| 19 Nov 2025 | Announcement | Keros Therapeutics Announces Preliminary Results of Tender Offer |
| 05 Nov 2025 | Announcement | Keros Therapeutics Reports Third Quarter 2025 Financial Results |
| 20 Oct 2025 | Announcement | Keros Therapeutics Commences Issuer Tender Offer to Repurchase up to $194.4 Million Shares |
| 15 Oct 2025 | Announcement | Keros Therapeutics Announces Plan for Return of $375 Million in Excess Capital |
| 08 Sep 2025 | Announcement | Keros Therapeutics Presents Additional Clinical Data from its KER-065 Program at the American Society of Bone and Mineral Research 2025 Annual Meeting |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |